K091291

Special 510(k) Summary of Safety and Effectiveness:
Xia® 3 Spinal System - Line Extension

JUN 24 2009

Proprietary Name:	Xia® 3 Spinal System – Line Extension
Common Name:	Spinal Fixation Appliances
Classification Name and Reference:	1) Spinal Interlaminal Fixation Orthosis, 21 CFR §888.3050 2) Spinal Intervertebral Body Fixation Orthosis, 21 CFR §888.3060 3) Pedicle Screw Spinal System, 21 CFR §888.3070 (b) (1) & (b) (2)
Device Product Code:	NKB, KWP, KWQ, MNH, MNI
Proposed Regulatory Class:	Class III
For Information contact:	Curtis Truesdale Regulatory Affairs Project Manager 2 Pearl Court Allendale, NJ 07401 Telephone: (201) 760-8296 Fax: (201) 760-8496 Email: Curtis.Truesdale@Stryker.com
Date Summary Prepared:	April 30, 2009
Predicate Devices	▪ Stryker Spine Xia® 3 Spinal System, K071373; ▪ Stryker Spine Xia® Spinal System, K080928; ▪ Stryker Spine Xia® Spinal System, K063428; ▪ Stryker Spine Radius® Spinal System, K062270, K082608; ▪ Stryker Spine Xia II Spinal System, K013823; and ▪ DePuy Spine Moss Miami Spinal System, K950697

K091291

Description of Device Modification	This 510(k) is intended to introduce an extension to the existing Xia® 3 Spinal System. The proposed line extension includes the addition of titanium Uniplanar Screws, titanium Uniplanar Reduction Screws, and use of the Stryker Spine Radius Ø5.5 mm Vitallium® rod with the Xia® 3 Spinal System.
Intended Use	The Xia® 3 Spinal System is intended for use in the noncervical spine. When used as an anterior/anterolateral and posterior, noncervical pedicle and non-pedicle fixation, the Xia® 3 Spinal System is intended to provide additional support during fusion using autograft or allograft in skeletally mature patients in the treatment of the following acute and chronic instabilities or deformities: degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies); spondylolisthesis; trauma (i.e., fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudoarthrosis; and failed previous fusion. The Ø5.5mm titanium and Vitallium® rods from the Stryker Spine Radius® Spinal System and Ø6.0mm Vitallium® rods from Xia® Spinal System are intended to be used with the other components of Xia® 3 Spinal System.
Summary of the Technological Characteristics	The Stryker Spine Xia® 3 Spinal System, with the incorporation of the subject components, is substantially equivalent to the predicate devices in terms of material, design, and indications for use. Engineering analysis and testing to demonstrate compliance with FDA's Guidance for Spinal System 510(k)'s May 3, 2004 were completed for the Stryker Spine Xia® 3 Spinal System.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN 24 2009

Stryker Spine
% Mr. Curtis D. Truesdale
Regulatory Affairs Project Manager
2 Pearl Court
Allendale, New Jersey 07401

Re: K091291
Trade/Device Name: Stryker Spine XIA® 3 Spinal System-Line Extension
Regulation Number: 21 CFR 888.3070
Regulation Name: Pedicle Screw Spinal System
Regulatory Class: III
Product Code: NKB, MNH, MNI, KWP, KWQ
Dated: June 2, 3009
Received: June 3, 2009

Dear Mr. Truesdale:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing

practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,



Mark N. Melkerson
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K091291
Device Name: Stryker Spine XIA® 3 Spinal System – Line Extension

Indications for Use:

The Stryker Spine XIA® 3 Spinal System is intended for use in the noncervical spine. When used as an anterior/anterolateral and posterior, noncervical pedicle and non-pedicle fixation system, the XIA® 3 Spinal System is intended to provide additional support during fusion using autograft or allograft in skeletally mature patients in the treatment of the following acute and chronic instabilities or deformities:

- Degenerative disc disease (DDD) (defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies);
- Spondylolisthesis;
- Trauma (i.e., fracture or dislocation);
- Spinal Stenosis;
- Curvatures (i.e., scoliosis, kyphosis, and/or lordosis);
- Tumor;
- Pseudoarthrosis; and
- Failed previous fusion.

The Ø5.5 mm titanium and Vitallium® rods from the Stryker Spine Radius® Spinal System and Ø6.0 mm Vitallium® rods from XIA Spinal System are intended to be used with the other components of XIA® 3 Spinal System.

Prescription Use ___X___ AND/OR Over-The-Counter Use _____

(21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(EXT for MXM)
(Division Sign-Off)
Division of Surgical Orthopedic,
and Restorative Devices

510(k) Number K 091291

Pg 1 of 1